Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition.

Kaoukis A, Deftereos S, Raisakis K, Giannopoulos G, Bouras G, Panagopoulou V, Papoutsidakis N, Cleman MW, Stefanadis C.

Curr Top Med Chem. 2013;13(2):95-114. Review.

PMID:
23470073
2.

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.

Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O.

PLoS One. 2012;7(10):e47662. doi: 10.1371/journal.pone.0047662.

3.
4.

Possible therapeutic role of endothelin antagonists in cardiovascular disease.

Ram CV.

Am J Ther. 2003 Nov-Dec;10(6):396-400. Review.

PMID:
14624276
5.

Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.

Price LC, Howard LS.

Am J Cardiovasc Drugs. 2008;8(3):171-85. Review.

PMID:
18533738
6.

Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.

Rubin LJ.

Life Sci. 2012 Oct 15;91(13-14):517-21. doi: 10.1016/j.lfs.2012.07.033. Review.

7.

Endothelin.

Kawanabe Y, Nauli SM.

Cell Mol Life Sci. 2011 Jan;68(2):195-203. doi: 10.1007/s00018-010-0518-0. Review.

8.

Endothelin antagonism with bosentan: current status and future perspectives.

Ono K, Matsumori A.

Cardiovasc Drug Rev. 2002 Winter;20(1):1-18. Review.

PMID:
12070530
9.

Endothelin receptor antagonists as disease modifiers in systemic sclerosis.

Shetty N, Derk CT.

Inflamm Allergy Drug Targets. 2011 Feb;10(1):19-26. Review.

PMID:
21184655
10.

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.

Steiner MK, Preston IR.

Vasc Health Risk Manag. 2008;4(5):943-52. Review.

11.

[The pharmacology of endothelin and its antagonist bosentan].

Clozel M, Roux S.

Ann Endocrinol (Paris). 2000 Feb;61(1):75-9. Review. French.

PMID:
10790596
12.

Endothelin antagonists.

Benigni A, Remuzzi G.

Lancet. 1999 Jan 9;353(9147):133-8. Review.

PMID:
10023915
13.

Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.

Spieker LE, Noll G, Lüscher TF.

Am J Cardiovasc Drugs. 2001;1(4):293-303. Review.

PMID:
14728028
14.

[Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].

Hoeper MM.

Dtsch Med Wochenschr. 2006 Dec 8;131(49 Suppl 9):S308-10. Review. German.

PMID:
17139593
15.

Endothelin receptor antagonists and cardiovascular diseases of aging.

Love MP, McMurray JJ.

Drugs Aging. 2001;18(6):425-40. Review.

PMID:
11419917
16.

[The role of endothelins in human cardiovascular disease].

Negrusz-Kawecka M.

Pol Merkur Lekarski. 2001 Nov;11(65):444-6. Review. Polish.

PMID:
11852820
17.

The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Ferro CJ, Webb DJ.

Drugs. 1996 Jan;51(1):12-27. Review.

PMID:
8741230
18.
19.

Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?

Spieker LE, Noll G, Ruschitzka FT, Lüscher TF.

J Am Coll Cardiol. 2001 May;37(6):1493-505. Review.

20.

[New expansion of endothelin research: perspectives for clinical application of endothelin-receptor antagonists].

Goto K, Miyauchi T.

Nihon Yakurigaku Zasshi. 2003 Feb;121(2):91-101. Review. Japanese.

PMID:
12616854

Supplemental Content

Support Center